BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 3538262)

  • 1. Patient accrual and interim statistical analysis in long-term randomized clinical trials: the French chronic lymphocytic leukemia CLL 80 protocol as a case study.
    Chastang C; Travade P; Benichou J; Dighiero G; Binet JL
    Stat Med; 1986; 5(5):465-73. PubMed ID: 3538262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic and therapeutic advances in CLL management: the experience of the French Cooperative Group. French Cooperative Group on Chronic Lymphocytic Leukemia.
    Semin Hematol; 1987 Oct; 24(4):275-90. PubMed ID: 3317854
    [No Abstract]   [Full Text] [Related]  

  • 3. Effectiveness of "CHOP" regimen in advanced untreated chronic lymphocytic leukaemia. French Cooperative Group on Chronic Lymphocytic Leukaemia.
    Lancet; 1986 Jun; 1(8494):1346-9. PubMed ID: 2872470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CHOP regimen versus intermittent chlorambucil-prednisone in stage B chronic lymphocytic leukemia. Short term results from a randomized clinical trial. French Cooperative Group on Chronic Lymphocytic Leukemia.
    Nouv Rev Fr Hematol (1978); 1988; 30(5-6):449-52. PubMed ID: 2906118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. CLL Trialists' Collaborative Group.
    J Natl Cancer Inst; 1999 May; 91(10):861-8. PubMed ID: 10340906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of chronic lymphocytic leukemia in advanced stages. A randomized trial comparing chlorambucil plus prednisone versus cyclophosphamide, vincristine, and prednisone.
    Montserrat E; Alcalá A; Parody R; Domingo A; García-Conde J; Bueno J; Ferrán C; Sanz MA; Giralt M; Rubio D
    Cancer; 1985 Nov; 56(10):2369-75. PubMed ID: 3899346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High dose chlorambucil versus Binet's modified cyclophosphamide, doxorubicin, vincristine, and prednisone regimen in the treatment of patients with advanced B-cell chronic lymphocytic leukemia. Results of an international multicenter randomized trial. International Society for Chemo-Immunotherapy, Vienna.
    Jaksic B; Brugiatelli M; Krc I; Losonczi H; Holowiecki J; Planinc-Peraica A; Kusec R; Morabito F; Iacopino P; Lutz D
    Cancer; 1997 Jun; 79(11):2107-14. PubMed ID: 9179056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of chronic lymphocytic leukemia using chlorambucil and prednisone with or without cycle-active consolidation chemotherapy. A Southeastern Cancer Study Group Trial.
    Keller JW; Knospe WH; Raney M; Huguley CM; Johnson L; Bartolucci AA; Omura GA
    Cancer; 1986 Sep; 58(6):1185-92. PubMed ID: 3527402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of chlorambucil and prednisone versus cyclophosphamide, vincristine, and prednisone as initial treatment for chronic lymphocytic leukemia: long-term follow-up of an Eastern Cooperative Oncology Group randomized clinical trial.
    Raphael B; Andersen JW; Silber R; Oken M; Moore D; Bennett J; Bonner H; Hahn R; Knospe WH; Mazza J
    J Clin Oncol; 1991 May; 9(5):770-6. PubMed ID: 2016618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of fludarabine, cyclophosphamide/doxorubicin/prednisone, and cyclophosphamide/doxorubicin/vincristine/prednisone in advanced forms of chronic lymphocytic leukemia: preliminary results of a controlled clinical trial. The French Cooperative Group on Chronic Lymphocytic Leukemia.
    Semin Oncol; 1993 Oct; 20(5 Suppl 7):21-3. PubMed ID: 8235691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Therapy of non-Hodgkin's lymphoma].
    Schaadt M; Plaumann L; Diehl V
    Dtsch Med Wochenschr; 1984 Feb; 109(7):261-5. PubMed ID: 6199176
    [No Abstract]   [Full Text] [Related]  

  • 12. Alternating pulses of vincristine-prednisone with cytarabine-cyclophosphamide versus vincristine-prednisone in the maintenance therapy of acute lymphoblastic leukemia.
    Sackmann Muriel F; Svarch E; Pavlovsky S; Bustelo P; Giuntoli J; Vergara B; Garay G; Eppinger-Helft M; Kvicala R; Dibar E
    Cancer Treat Rep; 1984 Apr; 68(4):581-6. PubMed ID: 6370428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Present status of chemotherapy in ALL and CLL].
    Ogawa M
    Gan To Kagaku Ryoho; 1982 Nov; 9(11):1882-7. PubMed ID: 6964032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statistical properties and use of sequential methods in randomized clinical trials when the response criterion is censored.
    Bénichou J; Chastang C
    Recent Results Cancer Res; 1988; 111():207-15. PubMed ID: 3175307
    [No Abstract]   [Full Text] [Related]  

  • 15. Response to fludarabine in B-cell chronic lymphocytic leukemia patients previously treated with chlorambucil as up-front therapy and a CHOP-like regimen as second line therapy.
    Liso V; Molica S; Capalbo S; Pogliani E; Battista C; Broccia G; Montillo M; Cuneo A; Leoni P; Specchia G; Castoldi G
    Haematologica; 2001 Nov; 86(11):1165-71. PubMed ID: 11694402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term results of the CHOP regimen in stage C chronic lymphocytic leukaemia. French Cooperative Group on Chronic Lymphocytic Leukaemia.
    Br J Haematol; 1989 Nov; 73(3):334-40. PubMed ID: 2690923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is the CHOP regimen a good treatment for advanced CLL? Results from two randomized clinical trials. French Cooperative Group on Chronic Lymphocytic Leukemia.
    Leuk Lymphoma; 1994 May; 13(5-6):449-56. PubMed ID: 8069190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination chemotherapy with the M-2 protocol (BCNU, cyclophosphamide, vincristine, melphalan, and prednisone) for chronic lymphocytic leukemia (stages III and IV).
    Case DC; Porensky RS; Fanning JP
    Oncology; 1985; 42(6):350-3. PubMed ID: 4069549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospectively randomized clinical trial of three intensive chemotherapy regimens for the treatment of advanced unfavorable histology non-Hodgkin's lymphoma.
    O'Connell MJ; Harrington DP; Earle JD; Johnson GJ; Glick JH; Carbone PP; Creech RH; Neiman RS; Mann RB; Silverstein MN
    J Clin Oncol; 1987 Sep; 5(9):1329-39. PubMed ID: 2442322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab for the first-line treatment of stage III-IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation.
    Papaioannou D; Rafia R; Rathbone J; Stevenson M; Buckley Woods H; Stevens J
    Health Technol Assess; 2012; 16(37):1-253, iii-iv. PubMed ID: 23021127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.